glioblastoma
Conditions
Interventions
Case series:autologous gp96+anti PD-1 treatment
Sponsors
Shenzhen Second People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Able to read and understand the informed consent document; must sign the informed consent; 2. Aged 18 to 75 years old; 3. Diagnosed supratentoria recurrent glioblastoma, Must have undergone a at least a 90% resection; 4. Availability of at least 4g tumor sample; 5. Karnofsky functional status rating > or equal to 70; 6. Patients with good compliance and follow-up should participate in the trial voluntarily; 7. Adequate bone marrow function, adequate liver function and adequate renal function.
Exclusion criteria
Exclusion criteria: 1. Inability to comply with study-related procedures; 2. patient not suitable for Neurosurgery; 3. Inavailability of at least 4g tumor sample or at least 6 doses of vaccine; 4. Patient with allergic constitution; 5. Unstable or severe intercurrent medical conditions; 6. Current diagnosis of Human Immunodeficiency Virus and Patients with active uncontrolled infection; 7. patients with any systemic disease needed to be treated with immunosuppressant or Corticosteroids; 8. any other cilical trials within 30 days pre-vaccination; 9. Female patients who are pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety profile of gp-96 and anti PD-1;survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;immunological parameter;quality of life; | — |
Countries
China
Contacts
Public ContactWei-ping Li
Shenzhen Second People's Hospital
Outcome results
None listed